Tests natural killer cell therapy after cord blood transplant in blood cancers
Tests natural killer cells after chemotherapy and cord blood transplant in people with leukemia.
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Registry title
- Personalized NK Cell Therapy in CBT
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 19 May 2016
- Expected to end
- 31 May 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Allogeneic Natural Killer Cell Line NK-92
- Anti-Thymocyte Globulin
- Busulfan
- Clofarabine
- Cyclophosphamide
- Fludarabine Phosphate
- Laboratory Biomarker Analysis
- Melphalan
- Rituximab
- Total-Body Irradiation
- Umbilical Cord Blood Transplantation
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 15 to 80 with blood cancers such as leukemia, lymphoma, myelodysplastic syndrome or multiple myeloma. They would have a cord blood transplant with natural killer cell therapy.
- Age
- 15 to 80 years. Age limit depends on the treatment plan: 15 to 45 years for one plan, 15 to 80 years for the others.
- Sex
- All sexes can join.
- Disease stage
- Blood cancers that came back, did not respond to treatment, or have high-risk features. Examples are acute leukemia, myelodysplastic syndrome, lymphoma, chronic leukemia and symptomatic multiple myeloma needing treatment.
- Earlier treatment
- People who have a treatment option known to remove all of the disease cannot join. Some groups must have had at least two standard treatments (small lymphocytic lymphoma or chronic lymphocytic leukemia).
- Biomarker or test result
- Some high-risk leukemia types are asked for by gene changes, such as translocations 9;22 or 4;11, or a flt3 mutation. Cord blood is chosen using HLA-KIR typing.
Main reasons for not taking part
- HIV positive
- Serious uncontrolled medical condition, such as ongoing blood infection or heart or lung failure
- Active central nervous system disease in people with a history of central nervous system cancer
- A willing, compatible related stem cell donor is available
- Karnofsky performance score below 60%
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Patients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics including complex karyotype, abnormal [abn][3q], -5/5q-, -7/7q-, abn[12p], abn[17p], myeloid/lymphoid or mixed-lineage leukemia [MLL] gene re-arrangement and t [6;9]47, fms related tyrosine kinase 3 [flt3] mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndromes (MDS), any disease beyond first remission
- Myelodysplastic syndrome (MDS): Primary or therapy related, including patients that will be considered for transplant; these include any of the following categories: 1) revised International Prognostic Scoring System (IPSS) intermediate and high risk groups, 2) malondialdehyde (MDA) with transfusion dependency, 3) failure to respond or progression of disease on hypomethylating agents, 4) refractory anemia with excess of blasts, 5) transformation to acute leukemia, 6) chronic myelomonocytic leukemia, 7) atypical MDS/myeloproliferative syndromes, 8) complex karyotype, abn(3g), -5/5g-, -7/7g-, abn(12p), abn(17p)
- Acute lymphoblastic leukemia (ALL): Induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease; patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease or acute biphenotypic leukemia, or double hit non-Hodgkin's lymphoma
- Non-Hodgkin's lymphoma (NHL) in second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant); relapsed double hit lymphomas; patients with options for treatment that are known to be curative are not eligible
- Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following a minimum of two lines of standard therapy
- Chronic myeloid leukemia (CML) second chronic phase or accelerated phase
- Hodgkin's disease (HD): Induction failures, after first complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant), or those with active disease
- Multiple myeloma: stage II or III, symptomatic, secretory multiple myeloma requiring treatment
- A person (such as a haploidentical family member) or unit of cord blood must be identified as a source of back-up cells source in case of engraftment failure
- Patient age criteria: age >= 15 and =< 45 years (myeloablative regimen 1; age >= 15 and =< 80 years (nonmyeloablative regimen 2) at the discretion of the investigator(s); age >= 15 and =< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen 3
- Performance score of at least 60% by Karnofsky
- Left ventricular ejection fraction of at least 40% (myeloablative regimen 1, reduced intensity regimen 3)
- Left ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)
- Pulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least 50% predicted value for hemoglobin concentration (myeloablative regimen 1, reduced intensity regimen 3)
- Serum creatinine within normal range, or if serum creatinine outside normal range, then renal function (measured or estimated creatinine clearance or glomerular filtration rate [GFR]) > 40mL/min/1.73 m\^2
- Serum glutamate pyruvate transaminase (SGPT)/bilirubin < to 2.0 x normal (myeloablative regimen 1), reduced intensity regimen 3; SGPT/bilirubin < to 4.0 x normal (nonmyeloablative regimen 2)
- Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months
- Patients with options for treatment that are known to be curative are not eligible
- Patients enrolled in this study may be enrolled on other supportive care investigational new drug (IND) studies at the discretion of the principal investigator (PI)
Who cannot take part
- Human immunodeficiency virus (HIV) positive; HIV results will be determined by nucleic acid testing
- Uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation (excluding primary disease for which cord blood [CB] transplantation is proposed), or psychiatric condition that would limit informed consent
- Active central nervous system (CNS) disease in patient with history of CNS malignancy
- Availability of appropriate, willing, human leukocyte antigen (HLA)-matched related stem cell donor
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 80 years old?
Where in United States
- M D Anderson Cancer CenterHouston, United StatesContact: Warren B Fingrut, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.
The 3 groups in the trial
- Myeloablative regimen 1Treatment being tested
Patients receive anti-thymocyte globulin IV over 4 hours on days -9 and -8, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -7 to -4. Patients undergo TBI on day -3. UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0. NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180.
Treatment: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Total-Body Irradiation, and Umbilical Cord Blood Transplantation
- Non-myeloablative regimen 2Treatment being tested
Patients with CD20 positive malignancies receive rituximab IV over 6 hours on day -9. Patients receive anti-thymocyte globulin IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 1 hour on days -6 to -3, and cyclophosphamide IV over 3 hours on day -6 and undergo TBI on day -1 at the discretion of the investigator(s). UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0. NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180.
Treatment: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Rituximab, Total-Body Irradiation, and Umbilical Cord Blood Transplantation
- Reduced intensity regimen 3Treatment being tested
Patients receive anti-thymocyte globulin IV over 4 hours on days -7 and -6, fludarabine phosphate IV over 1 hour on days -5 to -2, and melphalan IV over 30 minutes on day -2. UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0. NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180.
Treatment: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, and Umbilical Cord Blood Transplantation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Personalized NK Cell Therapy in CBT
- Plain-language title
- Tests natural killer cell therapy after cord blood transplant in blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT02727803, who can take part
- Record updated
- 2 November 2026